Incidence in ovarian cancer appears to be higher with combined data from several nonrandomised series putting the risk of GIP with bevacizumab in ovarian cancer at 5.4% (nearly twice the risk in colorectal cancer 3.1%), [60]. This evidence concerns the gene GIP and ovarian carcinoma.